Basic Information
TABRECTA FILM-COATED TABLET 150mg
TABLET, FILM COATED
Regulatory Information
SIN16350P
October 22, 2021
Prescription Only
Therapeutic
ORAL
August 10, 2023
May 30, 2025
Company Information
NOVARTIS (SINGAPORE) PTE LTD
NOVARTIS (SINGAPORE) PTE LTD
Active Ingredients
Capmatinib dihydrochloride monohydrate eqv Capmatinib
Strength: 150mg
Detailed Information
Contraindications
**5 Contraindications** None.
Indication Information
**3 Indications** Tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a MET exon 14 skipping mutation.